SeaStar Medical Holding (ICU) Liabilities and Shareholders Equity (2020 - 2026)
SeaStar Medical Holding's (ICU) quarterly Liabilities and Shareholders Equity came in at $11.3 million in Q1 2026, down 20.68% YoY from $14.2 million in Q1 2025, and down 20.45% on a QoQ basis from $14.2 million in Q4 2025.
SeaStar Medical Holding (ICU) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
SeaStar Medical Holding (ICU) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $11.3 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 20.68% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.3 million (up 82.99% YoY) and the FY2025 annual result came in at $14.2 million, up 201.23% from the prior year.
- Liabilities and Shareholders Equity fell to $11.3 million in Q1 2026, from $14.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $107.3 million in Q3 2022 to a low of $2.5 million in Q3 2023.
- A 5-year average of $24.6 million and a median of $7.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 403.81% — and 2023, when it tumbled 97.66%.
- Tracing ICU's Liabilities and Shareholders Equity over 5 years: stood at $3.0 million in 2022, then grew by 15.64% to $3.5 million in 2023, then jumped by 33.79% to $4.7 million in 2024, then jumped by 201.23% to $14.2 million in 2025, then dropped by 20.45% to $11.3 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $11.3 million (Q1 2026), $14.2 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | SeaStar Medical Holding | 13.68 Mn | 6.68 Mn | 561,000.00 | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.65 Mn |
| Mar 31, 2026 | 11.26 Mn |
| Dec 31, 2025 | 14.16 Mn |
| Sep 30, 2025 | 15.50 Mn |
| Jun 30, 2025 | 8.40 Mn |
| Mar 31, 2025 | 14.20 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 3.47 Mn |
| Mar 31, 2024 | 7.74 Mn |
| Dec 31, 2023 | 3.51 Mn |
| Sep 30, 2023 | 2.51 Mn |
| Jun 30, 2023 | 2.60 Mn |
| Mar 31, 2023 | 3.65 Mn |
| Dec 31, 2022 | 3.04 Mn |
| Sep 30, 2022 | 107.34 Mn |
| Jun 30, 2022 | 105.95 Mn |
| Mar 31, 2022 | 105.96 Mn |
| Dec 31, 2021 | 603,000.00 |
| Sep 30, 2021 | 106.20 Mn |